625 reports of this reaction
2.0% of all PANITUMUMAB reports
#11 most reported adverse reaction
COLORECTAL CANCER METASTATIC is the #11 most commonly reported adverse reaction for PANITUMUMAB, manufactured by Amgen, Inc. There are 625 FDA adverse event reports linking PANITUMUMAB to COLORECTAL CANCER METASTATIC. This represents approximately 2.0% of all 31,648 adverse event reports for this drug.
Patients taking PANITUMUMAB who experience colorectal cancer metastatic should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
COLORECTAL CANCER METASTATIC is a less commonly reported adverse event for PANITUMUMAB, but still significant enough to appear in the safety profile.
In addition to colorectal cancer metastatic, the following adverse reactions have been reported for PANITUMUMAB:
The following drugs have also been linked to colorectal cancer metastatic in FDA adverse event reports:
COLORECTAL CANCER METASTATIC has been reported as an adverse event in 625 FDA reports for PANITUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
COLORECTAL CANCER METASTATIC accounts for approximately 2.0% of all adverse event reports for PANITUMUMAB, making it a notable side effect.
If you experience colorectal cancer metastatic while taking PANITUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.